RxDoctor Payments Data

Katie Cupp, APRN

Nurse Practitioner · Las Vegas, NVNPI 1710343108

Payments from drug & device makers

$2,491in general payments, 2019–2025

Across 35 payments — averaging $71.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • AstraZeneca$481
  • GSK$330
  • Boehringer Ingelheim$149
  • Sanofi-aventis U.S. LLC$139
  • Regeneron Healthcare Solutions, Inc.$97
  • plus $274 from 6 others

What the payments were for

  • Consulting fees$63025%
  • Travel & lodging$331%
  • Food & beverage$1,52961%
  • Education$30012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,491 in reported general payments places this provider in the 85th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$214,807
Medicare patients
748
Services billed
3,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter292$228,344
Dupixent PenDupilumab32$123,342
Spiriva RespimatTiotropium Bromide76$48,515
Breztri AerosphereBudesonide/Glycopyr/Formoterol54$46,006
Breo ElliptaFluticasone/Vilanterol49$27,303
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$15,415
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$14,724
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,348
Arnuity ElliptaFluticasone Furoate31$11,450
Incruse ElliptaUmeclidinium Bromide12$9,685
Advair DiskusFluticasone Propion/Salmeterol34$7,733
Wixela InhubFluticasone Propion/Salmeterol72$7,505
Albuterol Sulfate HfaAlbuterol Sulfate216$7,124
SymbicortBudesonide/Formoterol Fumarate25$6,476
Combivent RespimatIpratropium/Albuterol Sulfate12$5,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$330$289,130406 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$149$68,613110 claims
AstraZenecaBreztri Aerosphere, Symbicort$481$52,48379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →